Kuros Biosurgery

Kuros is a biotechnology company that develops novel biologics and biomaterial combinations for localised therapy.

Kuros products retain biologically active molecules at the site of action by incorporation into injectable matrices. These products combine the ease of injectablity with localised delivery, tunable release profiles and safety. Kuros can use natural (fibrin-based) or synthetic matrices and has a number of methodologies for the retention and release of the biologically active molecules.Kuros’ most advanced products are in the fields of tissue repair and regeneration. These products are in various stages of clinical development and have already shown clinical benefits in wound healing and bone repair. The products consist of fusion proteins of naturally occurring bioactive factors covalently incorporated into fibrin matrices. This approach attempts to mimic the body’s natural healing process: sealing a wound with fibrin which retains stimulatory growth factors that are released as repair takes place.
In addition, Kuros is developing a portfolio of proprietary products which are addressing a number of significant additional therapeutic areas including other trauma, synthetic sealant and anti-adhesion indications.

Since its creation in 2000, Kuros has raised over $40 million. The company is located in Zurich, Switzerland.

Recent News

June 2, 2010
Kuros completes patient recruitment in Phase IIb study of KUR-113 in patients with tibial shaft fractures

March 15, 2010
Kuros meets primary efficacy endpoint in Phase IIb study with KUR-111

August 12, 2009
Kuros announces encouraging Phase IIa data with KUR-212 in patients with burns requiring mesh grafting

July 7, 2009
Kuros starts Phase IIb clinical trial with DUR-211 for diabetic foot ulcers

June 8, 2009
Kuros Completes patient recruitment in a phase IIb trial of KUR-111 in patients with tibal plateau fractures

September 23, 2008
Kuros and Aeris Announce Exclusive License Agreement in the Field of Lung Volume Reduction

February 22, 2007
Kuros receives orphan drug designation for a novel fusion protein for the treatment of solitary bone cysts

February 5, 2007
Kuros starts Phase II clinical trial in bone regeneration

Company Info

Country:	Switzerland
Industry:	LS
Sector:	biotechnology
Status:	Unrealized
Vehicle:	Genevest

Key persons

Didier Cowling, CEO; Dominik Ellenrieder, co-Founder & board member.

Company website

www.kuros.ch

Endeavour Vision Team

Daniel Bertholet

Sven Lingjaerde

		"The partners have been very supportive of our approach and stepped in to add value when needed. I would strongly recommend them as investors." Didier Cowling, Founder and CEO, Kuros Biosurgery AG
		"In preparing for our dual IPOs on the Nasdaq and Neuer Markt, it was very important for SCM Microsystems to gain insight and access to the European investment scene. This team helped SCM build the foundation for our successful offerings not only with capital, but with sound guidance and value-added services as well." Robert Schneider, founder and CEO, SCM Microsystems Inc.
		"VC is about funding your project but it is more about extending your core team. Thus, it is about partnering with those who are great to work with and are team players. Those, who understand your business and embrace your vision. Those, who know how to challenge your execution and to bring value. This is why I recommend Endeavour Vision team to entrepreneurs looking for funding." Dr. Georges Karam, co-Founder, President & CEO, Sequans
		"With Endeavour Vision we have been able to establish at fast speed the personal trust level needed and also come to terms very quick. They are highly professional partners and support us in every possible manner." Christian Lindner, Co-Founder and CEO Retailo AG
		"The Endeavour Vision team have been much more supportive and additive than others I have worked with the past. When our company was spun-off from Danfoss incubator, they gave us a great amount of support in the administrative load of a start-up, and worked hard to learn the details of the market and opportunity. Consequently, they have supported our company tremendously over the years, from day-to-day operations to strategic direction." James Peterson, CEO and Vice-Chairman, CeQur SA
		"We wanted a Venture Capital investor who was prepared to share our vision to create a global European company. The quality of their track record, the way they are helping us take our company to the next level, and the pure scale of their ambition make them a pleasure to work with." Boris Saragaglia, CEO, Spartoo.com
		"Not only do Endeavour Vision partners demonstrate relentless long term support standing strong and reliable leading shareholders, but they also bring tremendous value by cross-fertilizing upcoming technologies if and when they make business sense." Claude Cosson, CEO, Perigee
		"Entrepreneurs tend to avoid as much as possible VC's but if you really need smart Venture money then put Endeavour Vision on the top of your list: they are smart, knowledgable, experienced and well connected." Fédéric Koehn, CEO, Neocutis
		"Endeavour Vision's team brought an in-depth knowledge of our field – highlighted by impressive and thorough 360° due diligence, the long-term perspective required to build substantial companies, outstanding experience of bringing venture to financial success and an uncommon sense for team work. This is "smart money" at its best." Jacques R. Essinger, CEO Symetis
		"The Endeavour Vision team has been very helpful to BIND on multiple levels. Their advice, contacts and support rank with the best." Scott Minick, CEO, BIND Biosciences